Work

97P Investigation of compensatory resistance mechanisms against the FGFR inhibitor in bladder cancer cell lines

Year: 2026

Type: article

Abstract: Erdafitinib is a pan FGFR inhibitor for locally advanced and metastatic urothelial carcinoma with susceptible FGFR2/FGFR3 alterations. Despite the initial clinical benefits, patients eventually develop resistance. This study aims to investigate the underlying compensatory resistance mechanisms against erdafitinib, leading to sustained cell survival in bladder cancer.

Source: ESMO Open

DOI: 10.1016/j.esmoop.2026.106239

Authors: A. Benish, C.M. Ascione, D. Esposito, R. Bianco, L. Formisano

Institutions: Scuola Superiore Meridionale, Federico II University Hospital, University of Naples Federico II

Language: English

Topic: Bladder and Urothelial Cancer Treatments

Subfield: Surgery

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: gold

Estimated APC paid: $3,910